ArticleClinical case reports2026
Neutropenia Potentially Associated With Remifentanil Administered for Respiratory Drive Suppression: A Case Report.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neutropenia Potentially Associated With Remifentanil Administered for Respiratory Drive Suppression: A Case Report.Clinical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Remifentanil-related neutropenia (< 500/μL) has not been previously described. We encountered it in an 81-year-old man after aortic surgery complicated by acute respiratory distress syndrome. While receiving remifentanil at 0.04-0.08 μg/kg/min to suppress excessive respiratory effort in the intensive care unit, his neutrophil count plummeted from 20,690/μL to 2400/μL. Suspect drugs were stopped and granulocyte colony-stimulating factor given, yet neutropenia persisted until remifentanil was withdrawn, after which neutrophils recovered. When respiratory status deteriorated, remifentanil was restarted, and neutropenia promptly recurred. The temporal relationship, dechallenge, and rechallenge strongly implicate remifentanil as the cause of this rare adverse reaction. This case highlights the need for vigilance regarding hematologic toxicity with any medication, even those without prior reports, and underscores the importance of prompt review and withdrawal of potential offending agents when severe neutropenia develops.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.